Nothing Special   »   [go: up one dir, main page]

RU2011140508A - Антигены хламидии - Google Patents

Антигены хламидии Download PDF

Info

Publication number
RU2011140508A
RU2011140508A RU2011140508/10A RU2011140508A RU2011140508A RU 2011140508 A RU2011140508 A RU 2011140508A RU 2011140508/10 A RU2011140508/10 A RU 2011140508/10A RU 2011140508 A RU2011140508 A RU 2011140508A RU 2011140508 A RU2011140508 A RU 2011140508A
Authority
RU
Russia
Prior art keywords
seq
nucleic acid
protein
antibody
vector
Prior art date
Application number
RU2011140508/10A
Other languages
English (en)
Inventor
Гвидо ГРАНДИ
Рената Мария ГРИФАНТИНИ
Оретта ФИНКО
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2011140508A publication Critical patent/RU2011140508A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

1. Белок, содержащий любую аминокислотную последовательность из SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 136 или SEQ ID NO: 140, для использования в терапии или диагностике.2. Белок, имеющий 50% или более идентичности последовательности с белком по п.1.3. Белок, содержащий фрагмент аминокислотной последовательности по п.1 или 2.4. Белок по п.3, в котором фрагмент содержит по меньшей мере 8 последовательных аминокислот из аминокислотной последовательности по п.1 или 2.5. Антитело, связывающееся с белком по любому из пп.1-4, для применения в терапии или диагностике.6. Молекула нуклеиновой кислоты, кодирующая белок или антитело по любому из пп.1-5, для применения в терапии или диагностике.7. Молекула нуклеиновой кислоты по п.6, содержащая любую нуклеотидную последовательность из SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 135 или SEQ ID NO: 139.8. Молекула нуклеиновой кислоты, содержащая фрагмент любой нуклеотидной последовательности из SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 или SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 135 или SEQ ID NO: 139.9. Молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, комплементарную молекуле нуклеиновой кислоты по любому из пп.6-8.10. Молекула нуклеиновой кислоты, содержащая нуклеотидные последовательности, имеющие 50% или более идентичности последовательности с молекулой нуклеиновой кислоты по любому из пп.6-9.11. Молекула нуклеиновой кислоты, с�

Claims (27)

1. Белок, содержащий любую аминокислотную последовательность из SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 136 или SEQ ID NO: 140, для использования в терапии или диагностике.
2. Белок, имеющий 50% или более идентичности последовательности с белком по п.1.
3. Белок, содержащий фрагмент аминокислотной последовательности по п.1 или 2.
4. Белок по п.3, в котором фрагмент содержит по меньшей мере 8 последовательных аминокислот из аминокислотной последовательности по п.1 или 2.
5. Антитело, связывающееся с белком по любому из пп.1-4, для применения в терапии или диагностике.
6. Молекула нуклеиновой кислоты, кодирующая белок или антитело по любому из пп.1-5, для применения в терапии или диагностике.
7. Молекула нуклеиновой кислоты по п.6, содержащая любую нуклеотидную последовательность из SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 135 или SEQ ID NO: 139.
8. Молекула нуклеиновой кислоты, содержащая фрагмент любой нуклеотидной последовательности из SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43 или SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 135 или SEQ ID NO: 139.
9. Молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, комплементарную молекуле нуклеиновой кислоты по любому из пп.6-8.
10. Молекула нуклеиновой кислоты, содержащая нуклеотидные последовательности, имеющие 50% или более идентичности последовательности с молекулой нуклеиновой кислоты по любому из пп.6-9.
11. Молекула нуклеиновой кислоты, способная гибридизоваться с молекулой нуклеиновой кислоты по любому из пп.6-10 в условиях высокой строгости.
12. Вектор, содержащий нуклеиновую кислоту по любому из пп.6-11, для применения в терапии или диагностике.
13. Клетка-хозяин, содержащая нуклеиновую кислоту или вектор по любому из пп.6-12, для применения в терапии или диагностике.
14. Композиция, содержащая белок, антитело, молекулу нуклеиновой кислоты, вектор или клетку-хозяина по любому предшествующему пункту, для применения в терапии или диагностике.
15. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по любому предшествующему пункту для применения в качестве вакцинной композиции.
16. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по любому предшествующему пункту для применения в качестве фармацевтического средства.
17. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по любому предшествующему пункту для применения в лечении, профилактике или диагностике хламидии.
18. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по п.17, для применения в лечении, профилактике или диагностике Chlamydia trachomatis.
19. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по любому предшествующему пункту для активации иммунного ответа у млекопитающего.
20. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по любому предшествующему пункту для активации продукции антител, способных нейтрализовать хламидийную инфекцию.
21. Белок или нуклеиновая кислота по любому из пп.1-19, где иммунный ответ представляет собой CD4+ Th1-клеточный ответ.
22. Применение белка, антитела, нуклеиновой кислоты, вектора или клетки-хозяина по любому из пп.1-13 в производстве лекарственного средства для лечения или профилактики инфекции, вызванной бактерией Chlamydia, в частности Chlamydia trachomatis.
23. Способ лечения, профилактики или диагностики хламидии у пациента, включающий введение терапевтически эффективного количества белка, антитела, нуклеиновой кислоты, вектора, клетки-хозяина или композиции по любому предшествующему пункту.
24. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по любому из пп.1-21 для применения в качестве лекарственного средства в сочетании с одним или несколькими дополнительными хламидийными антигенами или кодирующими их нуклеиновыми кислотами.
25. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по п.24, где сочетание содержит СТ279+СТ601, СТ372+СТ443, СТ733+СТ153, СТ456+СТ381, СТ279+СТ153+СТ733+СТ601, СТ279+СТ601+СТ372+СТ443, СТ823+СТ733+СТ043+СТ456, СТ387+СТ812+СТ869, СТ387+СТ812С+СТ869 (или их варианты).
26. Белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция по п.24 или 25, где белок, антитело, нуклеиновая кислота, вектор, клетка-хозяин или композиция и один или несколько дополнительных хламидийных антигенов или кодирующих их нуклеиновых кислот представляют собой комбинированный препарат для одновременного, раздельного или последовательного введения.
27. Способ диагностики хламидийной инфекции, включающий:
(a) активацию продукции антитела против белка по любому из пп.1-4;
(b) контактирование антитела этапа (а) с биологическим образцом, предположительно, инфицированным хламидией, в условиях, подходящих для образования комплексов антиген-антитело; и
(c) выявление указанных комплексов, где обнаружение указанного комплекса является признаком хламидийной инфекции.
RU2011140508/10A 2009-03-06 2010-03-08 Антигены хламидии RU2011140508A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15792109P 2009-03-06 2009-03-06
US61/157,921 2009-03-06
PCT/IB2010/050988 WO2010100632A2 (en) 2009-03-06 2010-03-08 Chlamydia antigens

Publications (1)

Publication Number Publication Date
RU2011140508A true RU2011140508A (ru) 2013-04-20

Family

ID=42199074

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011140508/10A RU2011140508A (ru) 2009-03-06 2010-03-08 Антигены хламидии

Country Status (9)

Country Link
US (5) US8568732B2 (ru)
EP (2) EP2403526B1 (ru)
JP (1) JP2012519482A (ru)
CN (1) CN102438650A (ru)
AU (1) AU2010220103A1 (ru)
CA (1) CA2754618A1 (ru)
ES (1) ES2733084T3 (ru)
RU (1) RU2011140508A (ru)
WO (1) WO2010100632A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
WO2007082105A2 (en) * 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
RU2011140508A (ru) * 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
US20120135025A1 (en) * 2010-10-20 2012-05-31 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US20150010591A1 (en) * 2011-09-30 2015-01-08 The University Of British Columbia Chlamydia antigen compositions and uses thereof
US20130095487A1 (en) * 2011-10-18 2013-04-18 University Of South Florida Interferon-Gamma Response as a Diagnostic Test for Persistent Chlamydial Infections
US9046530B2 (en) * 2011-12-02 2015-06-02 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection
CN113940994B (zh) * 2021-11-09 2023-09-15 南华大学 壳聚糖-Pickering乳液白细胞介素12佐剂体系的制备方法及其应用
WO2023187743A1 (en) * 2022-03-31 2023-10-05 The University Of Queensland Improved chimeric polypeptides and uses thereof

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2049287C (en) 1989-03-21 2005-03-29 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CA2066053C (en) 1989-08-18 2001-12-11 Harry E. Gruber Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
AU657111B2 (en) 1990-12-20 1995-03-02 Dana-Farber Cancer Institute Control of gene expression by ionizing radiation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
HU222247B1 (hu) 1991-03-01 2003-05-28 Minnesota Mining And Manufacturing Company 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható 1H-imidazo[4,5-c]kinolin-5N-oxid-származékok
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CA2167042A1 (en) 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE215989T1 (de) 1993-09-15 2002-04-15 Chiron Corp Rekombinanter alphavirus vektor
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
EP0729351B1 (en) 1993-11-16 2000-09-13 SkyePharma Inc. Vesicles with controlled release of actives
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
WO1999027105A2 (en) 1997-11-21 1999-06-03 Genset Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CA2309228A1 (en) 1997-11-28 1999-06-10 Genset S.A. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
JP2001524533A (ja) 1997-12-02 2001-12-04 パウダージェクト ヴァクシンズ，インコーポレイテッド 粒子状ワクチン組成物の経皮的送達
CA2320223A1 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
KR100682154B1 (ko) 1998-05-07 2007-02-12 코릭사 코포레이션 아쥬번트 조성물 및 그의 사용방법
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN100558401C (zh) 1998-10-16 2009-11-11 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
EP1133572A4 (en) 1998-11-12 2005-06-15 Univ California GENOME SEQUENCE OF CHLAMYDIA PNEUMONIAE
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ATE469222T1 (de) 1998-12-08 2010-06-15 Corixa Corp Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ATE384793T1 (de) 1999-09-20 2008-02-15 Aventis Pasteur Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
CA2395499C (en) 1999-12-22 2011-10-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US6339133B1 (en) 2000-07-05 2002-01-15 Solvay Polyolefins Europe - Belgium Emergency stop of a polymerization in the gas phase
WO2002018383A2 (en) 2000-09-01 2002-03-07 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
KR100894767B1 (ko) 2000-09-26 2009-04-24 이데라 파마슈티칼즈, 인코포레이티드 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
EP2316482A1 (en) 2001-03-19 2011-05-04 Intercell USA, Inc. Transcutaneous immunostimulation
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20030099668A1 (en) 2001-09-14 2003-05-29 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
JP4493337B2 (ja) 2001-11-27 2010-06-30 アナディス ファーマシューティカルズ インク ３−β−Ｄ−リボフラノシルチアゾロ［４，５−ｄ］ピリミジンヌクレオシド及びその使用
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US20050106162A1 (en) * 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
AU2003226211B2 (en) 2002-03-29 2008-05-29 Novartis Vaccines And Diagnostics, Inc. Substituted benzazoles and use thereof as RAF kinase inhibitors
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003268184A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
CA2513655C (en) 2003-01-21 2011-11-22 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
US20070003568A1 (en) * 2003-02-24 2007-01-04 Alice Dautry-Varsat Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
CA2526106A1 (en) * 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
JP2007531768A (ja) 2004-03-31 2007-11-08 ニューヨーク・ユニバーシティ 感染症、癌および自己免疫疾患を治療するための新規な合成ｃ−糖脂質、その合成および使用
PL1742659T3 (pl) 2004-04-05 2013-08-30 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie oraz kompozycje szczepionek
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
EP1976557A2 (en) * 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Chlamydial antigens
WO2009109860A2 (en) 2008-03-06 2009-09-11 Novartis Ag Mutant forms of chlamydia htra
RU2011140508A (ru) * 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии

Also Published As

Publication number Publication date
JP2012519482A (ja) 2012-08-30
US9151756B2 (en) 2015-10-06
EP2403526B1 (en) 2019-05-15
US8568732B2 (en) 2013-10-29
WO2010100632A2 (en) 2010-09-10
AU2010220103A1 (en) 2011-09-22
ES2733084T3 (es) 2019-11-27
US9675683B2 (en) 2017-06-13
CA2754618A1 (en) 2010-09-10
US20120093851A1 (en) 2012-04-19
WO2010100632A3 (en) 2011-01-20
CN102438650A (zh) 2012-05-02
US20180092970A1 (en) 2018-04-05
EP2403526A2 (en) 2012-01-11
US20160158337A1 (en) 2016-06-09
US20140093510A1 (en) 2014-04-03
EP3549602A1 (en) 2019-10-09
US20190282685A1 (en) 2019-09-19
US10716842B2 (en) 2020-07-21

Similar Documents

Publication Publication Date Title
RU2011140508A (ru) Антигены хламидии
JP2005511076A5 (ru)
RU2004121149A (ru) Иммунизация против chlamydia trachomatis
JP2011250797A5 (ru)
JP2010516290A5 (ru)
JP2010166921A5 (ru)
De Amicis et al. Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes
WO2012048553A1 (zh) 大肠杆菌TolC抗原及其抗体与应用
EP3587440B1 (en) Human pd-l1 high-protein-affinity peptide and use thereof
TW201313248A (zh) 抗體及含抗體之組成物
RU2015102027A (ru) Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов
RU2016133598A (ru) Композиция микобактериального антигена
Sharma et al. Identification and immunogenic potential of B cell epitopes of outer membrane protein OmpF of Aeromonas hydrophila in translational fusion with a carrier protein
Nouri et al. Enhancement of long-lasting immunoprotective effect against Androctonus australis hector envenomation using safe antigens: Comparative role of MF59 and Alum adjuvants
CN107261127A (zh) 免疫活性组合物
CN105451762A (zh) 艰难梭菌疫苗及使用方法
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
KR20210029217A (ko) 염증성 장 질환을 치료하기 위한 조성물 및 방법
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
Khani et al. Introducing a cost-effective method for purification of bioactive flagellin from several flagellated gram-negative bacteria
Thulasitha et al. A proto-type galectin-2 from rock bream (Oplegnathus fasciatus): Molecular, genomic, and expression analysis, and recognition of microbial pathogens by recombinant protein
SA110310855B1 (ar) استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
RU2009113831A (ru) Ipad-белок шигеллы и его применение в качестве вакцины против шигеллезных инфекций
JP2020518575A5 (ru)
JP2000509961A (ja) 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体